CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Evans, Matthew C ^a   Gaillard, Pieter J ^b   de Boer, Marco ^b   Appeldoorn, Chantal ^b   Dorland, Rick ^b   Sibson, Nicola R ^a   Turner, Martin R ^a   Anthony, Daniel C ^a   Stolp, Helen B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b To BBB Technologies BV   (Netherlands)

Author keywords

Astrocytes; MRI; SOD1G93A; Steroids; Vacuolation

Indexed keywords

GLUCOCORTICOID; GLUTATHIONE; MACROGOL DERIVATIVE; METHYLPREDNISOLONE; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; AREA UNDER THE CURVE; BODY WEIGHT; CELL SURVIVAL; CELL VACUOLE; CENTRAL NERVOUS SYSTEM; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; GLIA; HUMAN; MOTONEURON; MOTOR ACTIVITY; MOUSE; PATHOLOGY; PHYSIOLOGY; TIME; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; AREA UNDER CURVE; BODY WEIGHT; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GLUCOCORTICOIDS; GLUTATHIONE; HUMANS; METHYLPREDNISOLONE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR NEURONS; NEUROGLIA; POLYETHYLENE GLYCOLS; SUPEROXIDE DISMUTASE; TIME FACTORS; VACUOLES;

EID: 84925547388     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-2-66     Document Type: Article

References (40)

1. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R: How common are the "common" neurologic disorders? Neurology 2007, 68(5):326-337.
2. Gurney ME: Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 1994, 331(25):1721-1722.
3. Zang DW, Yang Q, Wang HX, Egan G, Lopes EC, Cheema SS: Magnetic resonance imaging reveals neuronal degeneration in the brainstem of the superoxide dismutase 1 transgenic mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 2004, 20(7):1745-1751.
4. Bucher S, Braunstein KE, Niessen HG, Kaulisch T, Neumaier M, Boeckers TM, Stiller D, Ludolph AC: Vacuolization correlates with spin-spin relaxation time in motor brainstem nuclei and behavioural tests in the transgenic G93A-SOD1 mouse model of ALS. Eur J Neurosci 2007, 26(7):1895-1901.
5. Evans MC, Serres S, Khrapitchev AA, Stolp HB, Anthony DC, Talbot K, Turner MR, Sibson NR: T-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS. J Cereb Blood Flow Metab 2014, 34(5):785-793.
6. Anthony DC, Couch Y, Losey P, Evans MC: The systemic response to brain injury and disease. Brain Behav Immun 2012, 26(4):534-540.
7. Papadimitriou D, Le Verche V, Jacquier A, Ikiz B, Przedborski S, Re DB: Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiol Dis 2010, 37(3):493-502.
8. Philips T, Robberecht W: Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 2011, 10(3):253-263.
9. Evans MC, Couch Y, Sibson N, Turner MR: Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2013, 53: 34-41.
10. Hall ED, Oostveen JA, Gurney ME: Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998, 23(3):249-256.
11. Alexianu ME, Kozovska M, Appel SH: Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001, 57(7):1282-1289.
12. Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, Takeuchi H, Doyu M, Sobue G: Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 2002, 80(1):158-167.
13. Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G, Przedborski S, Rothstein JD: Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Annals of neurology 2002, 52(6):771-778.
14. Karlsson J, Fong KS, Hansson MJ, Elmer E, Csiszar K, Keep MF: Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neurosurg 2004, 101(1):128-137.
15. Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, Calingasan NY, Schafer P, Muller GW, Stewart C, Hensley K, Beal MF: Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006, 26(9):2467-2473.
16. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF: Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004, 88(3):576-582.
17. Gonzalez Deniselle MC, Gonzalez SL, De Nicola AF: Cellular basis of steroid neuroprotection in the wobbler mouse, a genetic model of motoneuron disease. Cell Mol Neurobiol 2001, 21(3):237-254.
18. Werdelin L, Boysen G, Jensen TS, Mogensen P: Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 1990, 82(2):132-134.
19. Koszdin KL, Shen DD, Bernards CM: Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: the role of P-glycoprotein. Anesthesiology 2000, 92(1):156-163.
20. Lindqvist A, Rip J, Gaillard PJ, Bjorkman S, Hammarlund-Udenaes M: Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. Mol Pharm 2013, 10(5):1533-1541.
21. Gaillard PJ, Appeldoorn CC, Rip J, Dorland R, van der Pol SM, Kooij G, de Vries HE, Reijerkerk A: Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release 2012, 164(3):364-369.
22. Gonzalez Deniselle MC, Gonzalez SL, Piroli GG, Lima AE, De Nicola AF: The 21-aminosteroid U-74389F increases the number of glial fibrillary acidic protein-expressing astrocytes in the spinal cord of control and Wobbler mice. Cell Mol Neurobiol 1996, 16(1):61-72.
23. Gonzalez Deniselle MC, Gonzalez SL, Lima AE, Wilkin G, De Nicola AF: The 21-aminosteroid U-74389F attenuates hyperexpression of GAP-43 and NADPH-diaphorase in the spinal cord of wobbler mouse, a model for amyotrophic lateral sclerosis. Neurochem Res 1999, 24(1):1-8.
24. Beato M: Gene regulation by steroid hormones. Cell 1989, 56(3):335-344.
25. Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A 1994, 91(2):752-756.
26. Phatnani HP, Guarnieri P, Friedman BA, Carrasco MA, Muratet M, O'Keeffe S, Nwakeze C, Pauli-Behn F, Newberry KM, Meadows SK, Tapia JC, Myers RM, Maniatis T: Intricate interplay between astrocytes and motor neurons in ALS. Proc Natl Acad Sci U S A 2013, 110(8):E756-E765.
27. Hardin-Pouzet H, Krakowski M, Bourbonniere L, Didier-Bazes M, Tran E, Owens T: Glutamate metabolism is down-regulated in astrocytes during experimental allergic encephalomyelitis. Glia 1997, 20(1):79-85.
28. Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, Sanberg PR: Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS One 2007, 2(11):e1205.
29. Andjus PR, Bataveljic D, Vanhoutte G, Mitrecic D, Pizzolante F, Djogo N, Nicaise C, Gankam Kengne F, Gangitano C, Michetti F, van der Linden A, Pochet R, Bacic G: In vivo morphological changes in animal models of amyotrophic lateral sclerosis and Alzheimer's-like disease: MRI approach. Anat Rec (Hoboken) 2009, 292(12):1882-1892.
30. Nicaise C, Mitrecic D, Demetter P, De Decker R, Authelet M, Boom A, Pochet R: Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res 2009, 1301: 152-162.
31. Jablonski MR, Jacob DA, Campos C, Miller DS, Maragakis NJ, Pasinelli P, Trotti D: Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis 2012, 47(2):194-200.
32. Rip J, Chen L, Hartman R, van den Heuvel A, Reijerkerk A, van Kregten J, van der Boom B, Appeldoorn C, de Boer M, Maussang D, de Lange EC, Gaillard PJ: Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats. J Drug Target 2014, 22(5):460-467.
33. Corcia P, Meininger V: Management of amyotrophic lateral sclerosis. Drugs 2008, 68(8):1037-1048.
34. Corcia P, Pradat PF, Salachas F, Bruneteau G, Forestier N, Seilhean D, Hauw JJ, Meininger V: Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler 2008, 9(1):59-62.
35. Chio A, Finocchiaro E, Meineri P, Bottacchi E, Schiffer D: Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study Group. Neurology 1999, 53(5):1123-1125.
36. Arora NS, Rochester DF: Respiratory muscle strength and maximal voluntary ventilation in undernourished patients. Am Rev Respir Dis 1982, 126(1):5-8.
37. Gelinas D: Patient and caregiver communications and decisions. Neurology 1997, 48: 9S-14S.
38. Turner MR, Grosskreutz J, Kassubek J, Abrahams S, Agosta F, Benatar M, Filippi M, Goldstein LH, van den Heuvel M, Kalra S, Lule D, Mohammadi B, first Neuroimaging Symosium in ALS (NISALS): Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 2011, 10(5):400-403.
39. Benatar M: Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007, 26(1):1-13.
40. West MJ, Slomianka L, Gundersen HJ: Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991, 231(4):482-497.